Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML

BACKGROUND: Overall survival remains poor in older patients with acute myeloid leukemia (AML) with less than 10% being alive after 5 years. In recent studies, a significant improvement in event-free, relapse-free and overall survival was shown by adding gemtuzumab ozogamicin (GO), a humanized antibo...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaramillo, Sonia, Krisam, Johannes, Le Cornet, Lucian, Kratzmann, Markus, Baumann, Lukas, Sauer, Tim, Crysandt, Martina, Rank, Andreas, Behringer, Dirk, Teichmann, Lino, Görner, Martin, Trappe, Ralf-Ulrich, Röllig, Christoph, Krause, Stefan, Hanoun, Maher, Hopfer, Olaf, Held, Gerhard, Buske, Sebastian, Fransecky, Lars, Kayser, Sabine, Schliemann, Christoph, Schaefer-Eckart, Kerstin, Al-Fareh, Yousef, Schubert, Jörg, Geer, Thomas, Kaufmann, Martin, Brecht, Arne, Niemann, Dirk, Kieser, Meinhard, Bornhäuser, Martin, Platzbecker, Uwe, Serve, Hubert, Baldus, Claudia D., Müller-Tidow, Carsten, Schlenk, Richard F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564967/
https://www.ncbi.nlm.nih.gov/pubmed/34732236
http://dx.doi.org/10.1186/s13063-021-05703-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564967/
https://www.ncbi.nlm.nih.gov/pubmed/34732236
http://dx.doi.org/10.1186/s13063-021-05703-w

Ejemplares similares